(Total Views: 189)
Posted On: 01/03/2018 11:33:41 AM
Post# of 25
Correct, $STLT is still fighting low volume, small audience. They had an opps issue about 18 months ago that cratered the stock price from $2 to about 30 cents, and then fixed it in an awesome way that rallied the stock back to about 90 cents and then sold off again. Ulta low floater, moves on air if volume hits it.
If they do the news / advertising on the new first ever product right, they could sell enough of it to close the cash bleed typical of early stage biotechs like $STLT.
For an early real-biotech to already have revenue and a retail product is novel. The stock price should retest the $2 level if the 10-Q in about 4-6 weeks knocks it out of the park. and if they PR it. Also a heavy following of retail customers could bring in retail investors.
If they do the news / advertising on the new first ever product right, they could sell enough of it to close the cash bleed typical of early stage biotechs like $STLT.
For an early real-biotech to already have revenue and a retail product is novel. The stock price should retest the $2 level if the 10-Q in about 4-6 weeks knocks it out of the park. and if they PR it. Also a heavy following of retail customers could bring in retail investors.
(0)
(0)
